Loading...
•
Dec 31, 2021
Sera Prognostics Q4 2021 Earnings Report
Reported financial results for the fourth quarter and full year 2021.
Key Takeaways
Sera Prognostics reported fourth quarter 2021 revenue of $26,000, compared to $6,000 for the same period in 2020. The net loss for the quarter was $12.5 million, compared to $5.4 million for the same quarter a year ago.
Our sales team is focusing geographically in high population density areas, where Anthem and other payers are concentrated.
The recent announcement of the MultiPlan contract is an example of this and we anticipate additional future announcements as we successfully contract with multiple types of payers.
CMS has set a Medicare payment rate of $750 for the existing unique Proprietary Laboratory Analysis (PLA) code, 0247U, for the PreTRM® Test.
Sera was added to the NASDAQ Biotechnology Index® (Nasdaq: NBI) effective Monday, December 20, 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...